Fintel reports that on May 10, 2024, JonesTrading initiated coverage of TriSalus Life Sciences (NasdaqGM:TLSI) with a Buy recommendation.
Analyst Price Forecast Suggests 66.02% Upside
As of May 8, 2024, the average one-year price target for TriSalus Life Sciences is 16.32. The forecasts range from a low of 16.16 to a high of $16.80. The average price target represents an increase of 66.02% from its latest reported closing price of 9.83.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for TriSalus Life Sciences is 31MM, an increase of 68.86%. The projected annual non-GAAP EPS is -2.20.
What is the Fund Sentiment?
There are 35 funds or institutions reporting positions in TriSalus Life Sciences. This is an increase of 14 owner(s) or 66.67% in the last quarter. Average portfolio weight of all funds dedicated to TLSI is 0.03%, an increase of 50.67%. Total shares owned by institutions increased in the last three months by 125.93% to 765K shares.
What are Other Shareholders Doing?
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 160K shares representing 0.60% ownership of the company. No change in the last quarter.
Geode Capital Management holds 126K shares representing 0.47% ownership of the company. In its prior filing, the firm reported owning 17K shares , representing an increase of 86.29%. The firm increased its portfolio allocation in TLSI by 957.93% over the last quarter.
HC Advisors holds 102K shares representing 0.38% ownership of the company.
FSMAX - Fidelity Extended Market Index Fund holds 67K shares representing 0.25% ownership of the company.
Hrt Financial holds 48K shares representing 0.18% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
